Updated on 30 July 2012
Singapore: Snoasis Medical has signed a distribution agreement with Hausten Healthcare, whereby Hausten Healthcare will distribute BioXclude in Japan. While BioXclude is not approved for use by the Japanese Ministry of Health and Welfare, clinicians may legally import unapproved foreign medical products for treatment of patients in accordance with the Pharmaceutical Affairs Law.
Hausten Healthcare is expected to begin distribution activities this coming fall. Highly proficient in managing this unique regulatory landscape, Hausten Healthcare works in conjunction with Japanese clinicians to easily and efficiently navigate the importation process. Mr Robert Tofe, president and founder of Snoasis Medical, said, "We are currently seeking regulatory approval in Taiwan and South Korea, and are actively working to set up distribution in China. Our relationship with Hausten allows access to Japan, one of the largest dental markets in the world, and punctuates our efforts to set up distribution throughout East Asia."
Amnion-chorion tissue is often referred to as the amniotic sac, the part of the placenta that encloses and protects the unborn baby through term. This tissue is considered immunoprivileged, possesses anti-bacterial and anti-microbial properties, reduces inflammation at the wound site, and provides a protein-enriched matrix to naturally facilitate epithelialization and improve overall wound healing. These attributes provide BioXclude with many benefits over traditional barrier membrane products used by dental professionals in guided bone and tissue regeneration procedures.
Founded in 2007, Snoasis Medical is focused on the development and commercialization of regenerative tissue and medical device products for use in dental surgery. In 2008, Snoasis obtained the exclusive license and worldwide distribution rights to all current and future placental tissue products processed by Surgical Biologics, A MiMedx Group Company (Kennesaw, GA) for use in dentistry. Snoasis Medical initiated commercial distribution of BioXclude in the US in March 2010 and in Canada in September 2010.
Hausten Healthcare, LLC is a newly formed entity focused on providing Japanese dental clinicians, institutions and patients the best possible tissue regenerative options, some of which are not currently approved by the Japanese Ministry of Health and Welfare. Created in June 2012, Hausten Healthcare was spun out of RHC Corporation, a company focused on providing Japanese physicians and medical institutions with a greater range of medical treatment options.